THE LEUKAEMIA FOUNDATION - National Research ProgramGrant Recipients - 2011 |
 |
PhD Scholarships |
funds per annum | |
Ms N. Anstee |
Genetic changes promoting AML and its resistance to therapy (AML) | more | $40,000 |
Ms N. Christie |
The role of the interleukin- 3 receptor on AML stem cells (AML) | more | $40,000 |
Ms J. Devlin |
Inhibiting cell signalling decreases ribosome synthesis and kills lymphoma cells (LYMPHOMA) | more | $40,000 |
Mr M. Lefebure |
Investigating combinations of drugs for the treatment of an incurable blood cancer (ALL BLOOD CANCERS) | more | $40,000 |
Ms H. Lim |
Roles of the bone and blood vessels in the development of blood disease (ALL BLOOD CANCERS) | more | $40,000 |
PhD (Clinical) Scholarships |
||
Dr A. Guirguis |
Targeting mechanisms of early cell death in myelodysplasia | more | $55,000 |
Dr T. Teh |
The role of a new potential therapeutic target that promotes survival of leukaemia cells | more | $55,000 |
Post-Doctoral Fellowships |
(Funding partnership with Cure Cancer Australia Foundation) | |
Dr S. Lane |
Treatment of blood diseases by targeting the disease-causing stem cells (ALL BLOOD CANCERS) | more | $100,000 |
Dr A. Ng |
Identification of genetic interactions predisposing to leukaemia (LEUKAEMIA) | more | $100,000 |
Dr F. Tzelepis |
Blood cancer patients' perceptions about the quality of care they receive (PSYCHOSOCIAL) | more | $94,723 |
Clinical Trial Grant
|
||
Dr A. Wei and Prof A. Spencer |
Investigating the role of targeted therapy with the FLT3 inhibitor for AML patients with FLT3 mutations (AML) | more | $198,000 |
Research Grants-in-Aid |
||
Ass Prof R. Lock et al. |
Improving treatment options for relapsed T-cell acute lymphoblastic) leukaemia (ALL) | more | $99,375 |
Dr M. McCormack & Dr C. Slape |
Targeting stem cells that cause T-cell leukaemia (LEUKAEMIA) | more | $100,000 |
Assoc Prof D. White & Prof T. Hughes |
Which kinase inhibitor is best for which CP-CML patient (CML) | more | $99,254 |
| Dr M. Guthridge Australian Centre for Blood Diseases, VIC |
New approaches to targeting the survival of AML cells (AML) | more | $99,736 |
| Associate Professor Richard D'Andrea The University of Adelaide, SA |
Dequalinium Chloride as a targeted therapy for Acute Myeloid Leukaemia (ALL) | | $100,000 |
Dr J. Dickinson et al. |
Finding causative genes for blood cancers (ALL BLOOD CANCERS) | more | $91,000 |
Dr S. Ting & Dr S. Russell |
Understanding how blood and leukaemia stem cells function (ALL BLOOD CANCERS) | more | $100,000 |
Dr R. Tothill et al. |
Defining the role of phosphoinositides in acute leukaemia (LEUKAEMIA) | more | $100,000 |
| Dr A. Wei & Prof C. Mitchell Monash University/Alfred Hospital, VIC |
Defining the role of phosphoinositides in acute leukaemia (LEUKAEMIA) | more | $100,000 |
Ass Prof N. Waterhouse |
How cells of the body’s immune system kill blood related malignancies (ALL BLOOD CANCERS) | more | $90,000 |
Prof G. Hill et al. |
Immune competence following bone marrow transplantation | more | $99,500 |
Dr P. Mollee et al. |
A clinical trial to improve the treatment of AL Amyloidosis | more | $100,500 |
Ass Prof D. Curtis & Prof S. Jane |
Helping blood cell numbers recover after transplantation or chemotherapy | more | $95,239 |
Prof D. Gottlieb |
A way of using a patient’s own immune system to stop severe infections caused by potent treatment given to patients with CLL (CLL) | more | $100,000 |
Dr S. Grist & Ass Prof B. Kuss |
Improving prognostic analysis of CLL through assessment of DNA repair: Y-H2A.X assay (CLL) | more | $100,000 |
Prof R. Christopherson & Ass Prof S. Mulligan |
Predicting risk and treatment response from patterns of surface markers on CLL (CLL) | more | $75,000 |
Dr S. Grist & Ass Prof B. Kuss |
Identifying patients at high risk of relapse in chronic lymphocytic leukaemia (CLL) | more | $25,000 |
Honours Scholarship |
||
Ms T.Nababan (di Giacomo Scholarship) |
How MLF1 affects blood stem cells | more | $10,000 |
Career Establishment Grant |
||
Dr Christina Brown |
The role of microRNAs in Acute Promyelocytic Leukaemia | $50,000 |
Cancer Australia PdCCRS Funding Partnership |
||
| Prof A. Lopez Centre for Cancer Biology, SA |
The role of CD123 in MDS and AML | $191,666 |
